DelveInsight’s, “CRISPR Therapies Pipeline Insight 2024” report provides comprehensive insights about 25+ CRISPR Therapies Companies and 30+ pipeline drugs in CRISPR Therapies pipeline landscape. It covers the CRISPR Therapies pipeline drug profiles, including clinical and nonclinical stage products. It also covers the CRISPR Therapies therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive CRISPR Therapies pipeline products in this space.

 

Key Takeaways from the CRISPR Therapies Pipeline Report

• DelveInsight’s CRISPR Therapies pipeline report depicts a robust space with 25+ CRISPR Therapies companies working to develop 25+ pipeline therapies for CRISPR Therapies treatment.
• The leading CRISPR Therapies Companies working in the market include Intellia Therapeutics, CRISPR therapeutics, Repare Therapeutics, Beam therapeutics, Caribou Biosciences, Emendo Biotherapeutics, Defence Therapeutics, Sarepta therapeutics, Editas Medicine, Locus Biosciences, Excision BioTherapeutics, AstraZeneca, Novartis, ASC therapeutics, Casebia therapeutics, Spotlight Therapeutics, KSQ Therapeutics, MEDIC Life Sciences, Scribe therapeutics, Arbor Biotechnologies, Sangamo therapeutics, Graphite Bio, Nuntius Therapeutics, and others.
• Promising CRISPR Therapies in the various stages of development include BD111 Adult single group Dose, HG202, CB-011, Cyclophosphamide, Fludarabine, Aldesleukin, EBT-101, and others.
• November 2023: HuidaGene Therapeutics Co. Ltd. announced a study of early phase 1 clinical trials for HG202. A Trial to Evaluate the Safety, Tolerability, and Efficacy of CRISPR-Cas13 RNA-editing Therapy Targeting Knockdown of Vascular Endothelial Growth Factor A (HG202) in the Treatment of Neovascular Age-related Macular Degeneration (nAMD).
• November 2023: Caribou Biosciences Inc. announced a study of Phase 1 clinical trials for CB-011. This is a Phase 1 study to evaluate the safety of CB-011 (the study treatment), an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets the B cell maturation antigen (BCMA), to determine the best dose of CB-011, and to assess the effectiveness of CB-011 in treating multiple myeloma that has come back (relapsed) or that is no longer responding to other treatment (refractory).

 

Request a sample and discover the recent advances in CRISPR Therapies Treatment Drugs @ CRISPR Therapies Pipeline Outlook Report

 

The CRISPR Therapies pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage CRISPR Therapies drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the CRISPR Therapies clinical trial landscape.

 

CRISPR Therapies Overview

CRISPRs are specialized stretches of DNA. “”CRISPR”” stands for “”clusters of regularly interspaced short palindromic repeats.”” It is a specialized region of DNA with two distinct characteristics: the presence of nucleotide repeats and spacers. Repeated sequences of nucleotides — the building blocks of DNA — are distributed throughout a CRISPR region.

 

Find out more about CRISPR Therapies Treatment Landscape @ Drugs for CRISPR Therapies Treatment

 

CRISPR Therapies Emerging Drugs Profile

• CTX001: CRISPR Therapeutics
• EDIT-101: Editas Medicine

 

CRISPR Therapies Pipeline Therapeutics Assessment

There are approx. 25+ key CRISPR Therapies companies which are developing the CRISPR Therapies. The CRISPR Therapies companies which have their CRISPR Therapies drug candidates in the most advanced stage, i.e. Phase I/II include, CRISPR therapeutics.

 

DelveInsight’s CRISPR Therapies Pipeline Report covers around 30+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

 

CRISPR Therapies pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

 

CRISPR Therapies Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

 

Learn more about the emerging CRISPR Therapies Pipeline Therapies @ CRISPR Therapies Clinical Trials Assessment

 

Scope of the CRISPR Therapies Pipeline Report

• Coverage- Global
• CRISPR Therapies Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• CRISPR Therapies Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• CRISPR Therapies Companies- Intellia Therapeutics, CRISPR therapeutics, Repare Therapeutics, Beam therapeutics, Caribou Biosciences, Emendo Biotherapeutics, Defence Therapeutics, Sarepta therapeutics, Editas Medicine, Locus Biosciences, Excision BioTherapeutics, AstraZeneca, Novartis, ASC therapeutics, Casebia therapeutics, Spotlight Therapeutics, KSQ Therapeutics, MEDIC Life Sciences, Scribe therapeutics, Arbor Biotechnologies, Sangamo therapeutics, Graphite Bio, Nuntius Therapeutics, and others.
• CRISPR Therapies- BD111 Adult single group Dose, HG202, CB-011, Cyclophosphamide, Fludarabine, Aldesleukin, EBT-101, and others.

 

Dive deep into rich insights for new drugs for CRISPR Therapies treatment, Visit @ CRISPR Therapies Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Executive Summary
3. CRISPR Therapies: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. Drug Name: Company Name
8. Drug profiles in the detailed report…..
9. Early Stage Products (Phase I/II)
10. CTX001: CRISPR Therapeutics
11. Drug profiles in the detailed report…..
12. Early stage products (Phase I)
13. LBP-EC01: Locus Biosciences
14. Drug profiles in the detailed report…..
15. Inactive Products
16. CRISPR Therapies Key Companies
17. CRISPR Therapies Key Products
18. CRISPR Therapies- Unmet Needs
19. CRISPR Therapies- Market Drivers and Barriers
20. CRISPR Therapies- Future Perspectives and Conclusion
21. CRISPR Therapies Analyst Views
22. CRISPR Therapies Key Companies
23. Appendix

 

For further information on the CRISPR Therapies pipeline therapeutics, reach out to CRISPR Therapies Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services